151751-Najiba-Chargi

289 Systemic therapy: skeletal muscle mass changes and chemoradiotherapy REFERENCES 1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer in - cidence, mortality, years of life lost, years lived with disability, and disability-adjust- ed life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer Collaboration. JAMA Oncol . 2017;3(4):524-548. doi:10.1001/jamaon - col.2016.5688 2. Bernier J, Domenge C, Ozsahin M, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med . 2004;350(19):1945-1952. doi:10.1056/ NEJMoa032641 3. Helfenstein S, Riesterer O, Meier UR, et al. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squa- mous cell carcinoma of the head and neck - A multicentre, retrospective analysis. Radiat Oncol . 2019;14(1):32. doi:10.1186/ s13014-019-1235-y 4. Muzumder S, Srikantia N, Vashishta GD, et al. Compliance, toxicity and effica - cy in weekly versus 3-weekly cisplatin concurrent chemoradiation in locally advanced head and neck cancer. J Radio- ther Pract . 2019;18(1):26-31. doi:10.1017/ S1460396918000341 5. Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - Results from an unselected cohort of the clinical cooperation group “personalized Radiotherapy in Head and Neck Cancer.” Radiat Oncol . 2020;15(1):7. doi:10.1186/s13014-019-1452-4 6. Hua X, Liu S, Liao JF, et al. When the Loss Costs Too Much: A Systematic Review and Meta-Analysis of Sarcopenia in Head and Neck Cancer. Front Oncol . 2020;9:1561. doi:10.3389/fonc.2019.01561 7. Kurk S, Peeters P, Stellato R, et al. Skel - etal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle . 2019;10(4):803-813. doi:10.1002/jcsm.12436 8. Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determi- nant of dose-limiting toxicity and neurop- athy in patients with colon cancer treat- ed with FOLFOX regimens. Cancer Med . 2016;5(4):607-616. doi:10.1002/cam4.621 9. Sjøblom B, Benth JŠ, Grønberg BH, et al. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity FromCarbo - platin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer. Clin Lung Cancer . 2017;18(2):e129-e136. doi:10.1016/j. cllc.2016.09.008 10. Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemothera- py. Clin Cancer Res . 2017;23(3):658-665. doi:10.1158/1078-0432.CCR-16-0940 11. Sealy MJ, Dechaphunkul T, Van Der Schans CP, et al. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. 2019. doi:10.1016/j. clnu.2019.02.029 12. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. 2017. doi:10.1016/j.oraloncol - ogy.2017.05.012 13. Garcia JM, Scherer T, Chen JA, et al. Inhi - bition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology . 2013;154(9):3118-3129. doi:10.1210/en.2013-1179 15